Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Stock Information for Clearside Biomedical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearside Biomedical Inc.

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York
Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference
Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.